IL-10-expressing Raw 264.7 cell line

Microencapsulated macrophages release conditioned medium able to prevent epithelial to mesenchymal transition.Epithelial to mesenchymal transition (EMT) has emerged as a key process in the development of renal fibrosis. In fact, EMT-derived fibroblasts contribute to the progression of chronic renal disease. In addition, anti-inflammatory M2 macrophages have exhibited a great influence on renal fibrosis. However, because […]

Contributors

Inventor Institute
Jose Luis Pedraz ; JesĂ?Ÿs Ciriza ; Laura Saenz del Burgo University of the Basque Country, EHU
Cat. #: 160550
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Research Fields: Cancer;Cell biology;Stem cell biology
Organism: Mouse
Growth properties: Adherent cells
Cancer Types In Detail: Epithelial to mesenchymal transition
Alternate name: IL-1, Interleukin 1
Product description: Microencapsulated macrophages release conditioned medium able to prevent epithelial to mesenchymal transition.Epithelial to mesenchymal transition (EMT) has emerged as a key process in the development of renal fibrosis. In fact, EMT-derived fibroblasts contribute to the progression of chronic renal disease. In addition, anti-inflammatory M2 macrophages have exhibited a great influence on renal fibrosis. However, because of the high impact that the inputs of different environmental cytokines have on their phenotype, macrophages can easily lose this property. This is why we aimed to modify the Raw 264.7 cell line in order to induce a M2 stable phenotype.M1 and M2 macrophages are main characters in the fibrotic process, chiefly preventing epithelial to mesenchymal transition (EMT). EMT, a process that make fully differentiated epithelial cells undergo transition to a fibroblast phenotype, has emerged as one important pathway in the development of renal fibrosis. Cells in EMT acquire mesenchymal migratory capacity and travel across the disrupted tubular basement membrane into the interstitial microenvironment. EMT-derived fibroblasts within the interstitium contribute to the progression of chronic kidney disease by facilitating deposition of interstitial extracellular matrix. The use of transplanted macrophages, pumping out active factors directly at the site, has proven to be an emergent technology in order to restore kidney function or modulate fibrosis through its role on EMT. However, macrophages, when transplanted in vivo, can lose their beneficial properties, depending on the environments. Thus, to preserve the macrophage regenerative effects, these cells were modified in order to induce and maintain their M2 phenotype.
Conditional: Yes
Conditional description: Il-10 is expressed as long as these cells are grown in media containing 10ug/ml of blasticidine.
Parental cell line: Raw 264.7
disease: Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Cells must be grown in blasticidine containing media (90% RPMI-1640 + 10% h.i. FBS).

Images

View Gallery
Figure showing that in cells microencapsulated in alginate matrices; Raw 264.7 modified cells (batch4.1LI; in pink) produce much more IL-10 than the same cells without modification (batch4.7C; control).

Related Tools for Cell lines

Cat. # Tool Name
151446 FLYRD18 Cell Line Key Info View Tool
151479 HCT 116 p300 KO [D10] Cell Line Key Info View Tool
151631 C-Raf KI D486A Cell Line Key Info View Tool
151663 MEF PKCe KO KI Cell Line Key Info View Tool
151665 MEF PKCe KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.